Powered By
Vaccines help train the immune system to recognize and respond to threats to the body. Though they’re typically used to prevent infectious diseases, vaccines are now in development to help prevent opioid overdose and support recovery.
Rather than acting on opioid receptors the way that medications such as methadone (Diskets, Methadose), buprenorphine (Brixadi, Sublocade), naltrexone (Vivitrol), and naloxone do, opioid vaccines train the immune system to produce antibodies that recognize a specific opioid and bind to it in the bloodstream before it reaches the brain.
In this article, learn about how opioid vaccines work, what research has been done, and what these vaccines could mean for people living with opioid use disorder (OUD).
Most vaccines work by exposing the immune system to an antigen, such as a protein from a virus or bacteria. Opioid molecules are too small for the immune system to recognize and respond to, so researchers address this problem with a three-part design for opioid vaccines.
The first part is a hapten, a molecule that mimics the target opioid. The second is a carrier protein, a large molecule that the immune system can recognize and react to. When joined together, the hapten and carrier protein help the immune system recognize the target opioid.
The third part is an adjuvant — an ingredient that helps produce a stronger immune response.
Together, the hapten, carrier protein, and adjuvant form a vaccine designed to train the body to produce antibodies specific to the opioid. If that opioid enters the bloodstream, the antibodies can bind to it and help keep it from reaching the brain.
Opioids bound by antibodies are too large to cross the blood-brain barrier, which helps protect the brain and central nervous system (CNS). By binding to the targeted opioid in the bloodstream, these antibodies may reduce the amount that reaches the brain. The antibodies are eventually broken down and cleared by the body.
However, protection from an opioid vaccine may not be complete, and an overdose could still occur.
Methadone, buprenorphine, naltrexone, and naloxone all work at the mu-opioid receptor on cells. Methadone fully activates mu-opioid receptors, while buprenorphine partially activates them. Naltrexone and naloxone block opioid receptors.
These medications can cause side effects. In people who are physically dependent on opioids, naltrexone or naloxone can trigger sudden withdrawal symptoms.
Opioid vaccines work differently because they don’t target opioid receptors. Instead, they’re designed to keep specific opioid molecules from reaching the brain. Because they target a particular opioid rather than the receptor, they may allow other medications containing other opioids, as well as medications such as naloxone, to continue working.
From early laboratory research to animal studies and now human trials, opioid vaccines have made progress. Here’s where research on opioid vaccines stands today.
Researchers have tested opioid vaccines in mice, rats, and primates to see whether they can target a specific opioid and not interfere with others.
In rats, a vaccine targeting oxycodone blocked oxycodone’s effects but not those of methadone, fentanyl, or naloxone. The effects lasted for two to three months after immunization.
Fentanyl vaccine studies in rats and mice had similar results. The vaccines blocked fentanyl’s effects but didn’t interfere with anesthetics, methadone, naloxone, oxycodone, or heroin.
Animal studies suggest that opioid vaccines should not interfere with naloxone’s ability to reverse opioid overdoses, but this has not yet been confirmed in humans.
Phase 1 trials are generally the first stage of human testing in clinical trials, intended to test the safety of a new treatment. Researchers test different doses and monitor side effects, but these trials generally aren’t designed to determine whether a treatment works.
Several clinical trials of opioid vaccines are underway, and most of them are in phase 1.
The Oxy(Gly)4-sKLH vaccine is being studied in an early-stage clinical trial involving people with OUD. The trial compares two doses of an oxycodone vaccine, high and low, with a placebo (an inactive substance). No results have been released, and the study is expected to be completed by March 2027.
A research team at the University of Washington reportedly received approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 human trials of a heroin vaccine.
Three human clinical trials of morphine vaccines were published between 2007 and 2012 outside the United States. The 2007 trial found that the vaccine was well tolerated, produced higher antibody levels at higher doses, and caused no serious side effects. Injection-site pain and tenderness were the most common side effects.
The trials showed that the morphine vaccines were generally well tolerated, but they didn’t establish whether the vaccines could prevent opioid overdose.
Fentanyl, a synthetic opioid, is a particular focus of opioid vaccine research because of its association with overdose deaths in the United States. Several fentanyl vaccine studies are underway.
One vaccine is awaiting approval to begin human trials. It’s being developed by the University of Washington research team that’s also studying a heroin vaccine.
A company called ARMR Sciences released interim findings from its ongoing phase 1/2 clinical trial of ARMR-100, a fentanyl vaccine, in June 2026. According to the company, the vaccine was well tolerated thus far, with no serious side effects and only minor ones, such as occasional headaches. The company plans to study whether the vaccine can prevent fentanyl’s effects.
People may be exposed to more than one opioid without knowing it. Multivalent opioid vaccines are designed to target several opioids at once. For example, one study published in 2025 tested a vaccine targeting both heroin and fentanyl.
Opioid vaccines may be promising because they don’t need to be taken daily, and early trial data suggests they’re generally well tolerated. In addition, opioid vaccines don’t have the potential for misuse associated with opioid drugs. However, they still have limitations, and more research is needed.
Opioid vaccines could be used alongside medications for OUD to help prevent overdose and support recovery. However, a vaccine wouldn’t replace existing treatments for cravings, withdrawal, or behavioral changes involved in recovery. This means a return to opioid use and an overdose could still happen, even after someone receives an opioid vaccine.
Researchers still don’t know how long protection from opioid vaccines can last or whether they can effectively prevent overdose in people with OUD.
Some opioid vaccine researchers have raised questions about who should have access to opioid vaccines. Researchers emphasize that if a vaccine is approved, it should be widely available and people should be able to choose to receive it.
Vaccine distribution raises concerns about situations in which consent isn’t always straightforward. Researchers worry that vaccination could become a requirement for getting treatment, avoiding jail time, or facing other consequences in the justice system. In addition, someone may not be able to give informed consent if they’re under the influence of drugs or immediately following an overdose.
Opioid vaccines are still being studied, and it’s unclear when they might become available. Meanwhile, researchers continue discussing how to make opioid vaccines available in a safe and ethical way.
If you have questions about what this research could mean for you, talk with your doctor about how opioid vaccines might fit into your recovery plan.
Get updates directly to your inbox.
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.